<?xml version="1.0" encoding="UTF-8"?>
<document id="29409816">
	<sentence id="s1" text="RAD51C and RAD51D have been defined as susceptibility genes for hereditary breast and ovarian cancer syndrome in several studies.">
		<entity id="s1.e1" charOffset="0-6"
			type="GENE" text="RAD51C" ontology_id="5889"/>
		<entity id="s1.e2" charOffset="11-17"
			type="GENE" text="RAD51D" ontology_id="5892"/>
		<entity id="s1.e3" charOffset="94-100"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e3" pgr="true"/>
		<pair id="s1.p2" e1="s1.e2"
		    e2="s1.e3" pgr="true"/>
	</sentence>
	<sentence id="s2" text="The RAD51C pathogenic variant c.404G AAAA A was identified in a breast and ovarian cancer family (0.7%), while the RAD51D pathogenic variant c.694C AAAA T was described in an ovarian cancer family (1.3%).">
		<entity id="s2.e1" charOffset="83-89"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s2.e2" charOffset="115-121"
			type="GENE" text="RAD51D" ontology_id="5892"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="true"/>
	</sentence>
	<sentence id="s3" text="These results increase our knowledge about the RAD51C and RAD51D mutation spectrum and support the notion that these genes should be included in the gene panel testing performed on patients with hereditary breast and ovarian cancer syndrome">
		<entity id="s3.e1" charOffset="47-53"
			type="GENE" text="RAD51C" ontology_id="5889"/>
		<entity id="s3.e2" charOffset="58-64"
			type="GENE" text="RAD51D" ontology_id="5892"/>
		<entity id="s3.e3" charOffset="225-231"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e3" pgr="true"/>
		<pair id="s3.p2" e1="s3.e2"
		    e2="s3.e3" pgr="true"/>
	</sentence>
</document>
